Back to top
more

Pacira BioSciences (PCRX)

(Real Time Quote from BATS)

$30.66 USD

30.66
274,246

+1.40 (4.79%)

Updated May 30, 2024 02:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PCRX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Pacira BioSciences, Inc. [PCRX]

Reports for Purchase

Showing records 281 - 300 ( 720 total )

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 281

05/06/2019

Daily Note

Pages: 10

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 282

05/03/2019

Company Report

Pages: 8

1Q19 Results in Line With Our Estimates; Competitor Setback Doesn?t Change Our Already Bullish View; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 283

04/09/2019

Company Report

Pages: 7

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 284

03/08/2019

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 285

03/08/2019

Daily Note

Pages: 9

Pacira to Acquire MyoScience for ioverao Non-Opioid Pain Management

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 286

03/08/2019

Company Report

Pages: 7

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 287

03/06/2019

Company Report

Pages: 9

Logical Non-Opioid Bolt-On Acquisition; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 288

03/04/2019

Company Report

Pages: 9

Q4 FY 18 Financials and 2019 Outlook.

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 289

03/01/2019

Company Report

Pages: 7

4Q18 Results; Strong 2019 Guidance in Face of a Potential Rival

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 290

02/04/2019

Company Report

Pages: 8

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 291

01/29/2019

Company Report

Pages: 9

Sales Continue to Grow; Positive Phase 4 C-section Results

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 292

01/18/2019

Industry Report

Pages: 9

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 293

01/14/2019

Industry Report

Pages: 9

HEALTHCARE - The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 294

01/06/2019

Industry Report

Pages: 10

The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 295

01/03/2019

Company Report

Pages: 5

The Beats Go on With 4Q18 Preannouncement; Stock Weakness Is Buying Opportunity With Operational Momentum Into 2019

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 10.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 296

01/03/2019

Company Report

Pages: 8

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 297

12/14/2018

Company Report

Pages: 8

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 298

11/12/2018

Company Report

Pages: 7

Price: 24.95

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 299

11/05/2018

Company Report

Pages: 10

Q3 Financials; EXPAREL? Sales Continue to Climb

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Pacira BioSciences, Inc.

Industry: Medical - Drugs

Record: 300

11/02/2018

Company Report

Pages: 7

3Q18 Results; Onward and Upward; Another Beat and Raise, and Reminder of the Operating Leverage; Increase Target to $60

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party